Why it may matterVerify against the original reporting
The Q2 results align with expectations; the 3870 ramp and quad-stack adoption point to stronger demand and potential gross-margin improvement in H2, supporting a near-term upside. The dividend and reaffirmed guidance reduce downside risk, though execution risk around ramp speed remains a consideration; historical IRMD reactions tend to move on progress of new platforms and bookings velocity.
AI summary
What happened, with direct paths to the underlying reporting
IRADIMED CORPORATION reported Q2 2026 revenue of $20.5 million, up 0.5% year over year, with GAAP EPS of $0.41 and non-GAAP EPS of $0.46. The company declared a quarterly dividend of $0.20 per share and reaffirmed full-year 2026 guidance of $91–$96 million in revenue and $1.90–$2.05 in GAAP EPS ($2.09–$2.24 non-GAAP). The highlight is progress on the 3870 MR IV pump ramp and record domestic monitor bookings, implying improving mix and potential margin upside in H2.
Q2 2026 revenue $20.5m. Up 0.5% YoY.
GAAP EPS: $0.41. Non-GAAP EPS: $0.46.
Dividend: $0.20 per share. Payable Aug 28, 2026.
3870 MR IV pump ramp underway. Quad-stack orders >70%.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
